The addition of neoadjuvant pertuzumab for the treatment of HER2+ breast cancer: a cost estimate with real-world data

Cost-Effectiveness Analysis of Pertuzumab with Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States

(2019) Louis P. Garrison et al.   VALUE IN HEALTH

Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

(2017) Hazel Squires et al.   PHARMACOECONOMICS

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

(2016) Luca Gianni et al.   LANCET ONCOLOGY

Economic Evaluation of Pertuzumab In Combination with Trastuzumab and Docetaxel in the Neoadjuvant Treatment of Women with HER2-Positive, Locally Advanced, Inflammatory or Early Breast Cancer in Portugal

(2016) Ribeiro et al.   VALUE IN HEALTH

Cost-Utility Analysis of Neoadjuvant Pertuzumab and Trastuzumab in Patients with Locally Advanced, Inflammatory, or Early HER-2 Positive Breast Cancer

(2016) Ignatyeva et al.   VALUE IN HEALTH

The Evolving Landscape of HER2 Targeting in Breast Cancer

(2015) Mark M. Moasser et al.   JAMA Oncology

Real world cost of human epidermal receptor 2-positive metastatic breast cancer patients: a longitudinal incidence-based observational costing study in the Netherlands and Belgium

(2014) G.W.J. Frederix et al.   EUROPEAN JOURNAL OF CANCER CARE

Cost-effectiveness analysis of neoadjuvant pertuzumab and trastuzumab therapy for locally advanced, inflammatory, or early HER2-positive breast cancer in Canada

(2014) C. L. Attard et al.   JOURNAL OF MEDICAL ECONOMICS

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

(2013) A. Schneeweiss et al.   ANNALS OF ONCOLOGY

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Population-based Estimate of the Prevalence of HER-2 Positive Breast Cancer Tumors for Early Stage Patients in the US

(2010) Kathleen A. Cronin et al.   CANCER INVESTIGATION